MiMedx Group (NASDAQ:MDXG) Rating Increased to Strong-Buy at StockNews.com

MiMedx Group (NASDAQ:MDXG) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday.

Several other analysts have also recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of MiMedx Group in a report on Tuesday, July 2nd. They issued an “overweight” rating and a $11.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Wednesday, May 1st. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Trading Up 0.3 %

Shares of MDXG stock opened at $7.13 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.29 and a quick ratio of 2.71. The firm has a market cap of $1.05 billion, a PE ratio of 16.20 and a beta of 1.99. The company has a 50-day moving average of $7.19 and a two-hundred day moving average of $7.53. MiMedx Group has a 1-year low of $5.57 and a 1-year high of $9.27.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.03. The company had revenue of $84.71 million during the quarter, compared to analyst estimates of $79.36 million. MiMedx Group had a net margin of 18.63% and a return on equity of 39.42%. On average, analysts predict that MiMedx Group will post 0.32 EPS for the current year.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MDXG. AJOVista LLC purchased a new stake in shares of MiMedx Group during the 4th quarter worth $25,000. Headlands Technologies LLC purchased a new stake in shares of MiMedx Group in the 1st quarter worth about $27,000. Entropy Technologies LP purchased a new stake in shares of MiMedx Group in the 1st quarter worth about $99,000. KMG Fiduciary Partners LLC purchased a new stake in shares of MiMedx Group in the 4th quarter worth about $105,000. Finally, Loudon Investment Management LLC purchased a new stake in shares of MiMedx Group in the 4th quarter worth about $105,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.